Discover investment opportunities in Biotech AI Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Biotech AI Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Biotech AI Stocks using our Smart AI Filter.
7 stocks found for "Biotech AI Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.36 Risk measure | ±26.9% Price volatility | 24.5 Valuation | 0.00% Annual yield | |||
0.89 Risk measure | ±41.9% Price volatility | 22.8 Valuation | 0.00% Annual yield | |||
1.34 Risk measure | ±55.5% Price volatility | -10.4 Valuation | 0.00% Annual yield | |||
1.06 Risk measure | ±44.4% Price volatility | -272.1 Valuation | 0.00% Annual yield | |||
1.19 Risk measure | ±53.7% Price volatility | -156.9 Valuation | 0.00% Annual yield | |||
0.70 Risk measure | ±46.8% Price volatility | 1.5 Valuation | 0.00% Annual yield | |||
0.30 Risk measure | ±26.0% Price volatility | 12.1 Valuation | 0.66% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Sarepta plummets after a third death in its muscular dystrophy program for investigational gene therapies, prompts FDA action and intensifies safety scrutiny.
Read moreIllumina Inc. ILMN is currently in Phase 17 of its 18-phase Adhishthana Cycle on the weekly chart. A detailed structural analysis using the Adhishthana Principles reveals deeper issues that go beyond short-term price action and offers compelling reasons why this stock should be avoided.
Read moreVertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read moreIn the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $52.73, denoting a -6.54% move from the preceding trading day.
Read moreThe average of price targets set by Wall Street analysts indicates a potential upside of 26.2% in Exact Sciences (EXAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read moreAlnylam Pharmaceuticals ALNY is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish structure.
Read more